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Glycosphingolipids are ubiquitous constituents of eukaryotic plasma membranes, and their sialylated derivatives, gangliosides,
are the major class of glycoconjugates expressed by neurons. Deficiencies in their catabolic pathways give rise to a large and
well-studied group of inherited disorders, the lysosomal storage diseases. Although many glycosphingolipid catabolic defects
have been defined, only one proven inherited disease arising from a defect in ganglioside biosynthesis is known. This disease,
because of defects in the first step of ganglioside biosynthesis (GM3 synthase), results in a severe epileptic disorder found at
high frequency amongst the Old Order Amish. Here we investigated an unusual neurodegenerative phenotype, most commonly
classified as a complex form of hereditary spastic paraplegia, present in families from Kuwait, Italy and the Old Order Amish.
Our genetic studies identified mutations in B4GALNT1 (GM2 synthase), encoding the enzyme that catalyzes the second step in
complex ganglioside biosynthesis, as the cause of this neurodegenerative phenotype. Biochemical profiling of glycosphingolipid
biosynthesis confirmed a lack of GM2 in affected subjects in association with a predictable increase in levels of its precursor,
GM3, a finding that will greatly facilitate diagnosis of this condition. With the description of two neurological human diseases
involving defects in two sequentially acting enzymes in ganglioside biosynthesis, there is the real possibility that a previously
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unidentified family of ganglioside deficiency diseases exist. The study of patients and animal models of these disorders will
pave the way for a greater understanding of the role gangliosides play in neuronal structure and function and provide insights
into the development of effective treatment therapies.
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Introduction
Glycosphingolipids (GSLs) are ubiquitous constituents of eukaryotic
plasma membranes, and their sialylated derivatives, gangliosides,
are the major class of glycoconjugates expressed by neurons
(Schnar, 2005). Deficiencies in their catabolic pathways give rise
to excessive intralysosomal accumulation of these lipids associated
with a large and well-studied group of inherited disorders, the
lysosomal storage diseases (Platt and Walkley, 2004; Ballabio
and Gieselmann, 2009). These disorders typically involve progres-
sive neurodegeneration and, for the majority of these diseases, no
effective treatment is available (Platt and Lachmann, 2009).
Although many GSL catabolic defects have been defined to date
(Ginzburg et al., 2004), very few are known to result from a
defect in GSL biosynthesis and previous reports of potential gan-
glioside biosynthesis disorders based on biochemical evidence have
not been proven genetically (Fishman et al., 1975). Proven dis-
orders include a defect in serine palmitoyltransferase long chain
subunit 1 (SPTLC1), which catalyzes the first step in sphingolipid
biosynthesis leading to downstream ceramide and sphingolipids
biosynthesis, which is associated with hereditary sensory and auto-
nomic neuropathy (HSAN1) (Bejaoui et al., 2001). However, these
patients retain the ability to synthesize GSLs by using L-alanine as
the precursor instead of serine. This results in the production of an
atypical class of deoxy-sphingolipids. A more selective defect has
also been described, termed ‘GM3 synthase deficiency’, which was
previously the only proven defect in ganglioside biosynthesis. This
novel human disease is a severe epileptic disorder identified
amongst families of the Old Order Amish community (Simpson
et al., 2004). Its existence led us to consider that other human
diseases, not yet identified, may exist that result from defects in
enzymes that function at different steps in the ganglioside biosyn-
thetic pathway (Lannert et al., 1998; Daniotti and Iglesias-
Bartolome, 2011). As gangliosides are conserved lipids, expressed
at high levels in the nervous system of mammals, we hypothesized
that any such conditions would likely display neurological (particu-
larly neurodegenerative) phenotypes.
In the current study, we investigated the genetic and molecular
basis of an unusual neurodegenerative phenotype, best described
as a complex form of hereditary spastic paraplegia. The hereditary
spastic paraplegias are among the most genetically diverse of all
inherited Mendelian disorders, with 450 distinct loci and 435
genes identified to date. They comprise a large group of neuro-
degenerative diseases characterized clinically by the presence of
lower limb spasticity, and pathologically by the retrograde degen-
eration of the longest nerve fibres in the corticospinal tracts and
posterior columns. The genes known to underlie hereditary spastic
paraplegia seem to encode molecules with a diverse range of cel-
lular functions, implicating numerous defective biological processes
in the pathogenesis of this disease (Blackstone et al., 2011). We
previously mapped a gene for a complex autosomal recessive form
of hereditary spastic paraplegia (SPG26) in a large Kuwaiti family
(Family 1, Fig. 1A) to a 34 Mb region of chromosome 12q
(Wilkinson et al., 2005). In the current study, we determined
that mutations in B4GALNT1, encoding GM2 synthase, are re-
sponsible for this condition. We also identified mutations in this
gene in an Italian-Canadian family as well as families from the Old
Order Amish community, in which the only other known disorder
relating to defective ganglioside biosynthesis has also been
described.
Materials and methods
Subjects
Blood or buccal samples were obtained from affected children, parents
and unaffected family members with informed consent. DNA and RNA
were extracted by standard procedures. A single 0.4-mm diameter skin
biopsy was taken from individuals from Family 2 IV:3, IV:4 (affected)
and IV:1 (unaffected), and family 3 VII:2 and VII:5 (affected). All
samples were obtained with approved informed consent. All affected
individuals underwent a detailed physical examination.
Exome and targeted regional
sequencing
Exome sequencing was undertaken in a single affected individual from
each family, using the SureSelect All Exons 50 Mb Target Enrichment
System (Agilent) and sequencing on a HiSeq (Illumina) with 76 bp
paired end reads. Single nucleotide variants were called using two
programs (GATK, SamTools) while insertion-deletions (indels) were
called using (GATK and Dindel). All variants were annotated using
dbSNP (132) and the 1000 Genomes pilot study. Single nucleotide
polymorphism effect predictor (VEP) was used for predicting the vari-
ant consequences on the protein structure based on Ensembl (version
61). Both single nucleotide variants and indels called by the three
programs were then merged into a single file for downstream analysis.
Variants were filtered out if the read depth was 54 or 41200 , if
the consensus quality was 520 or if the single nucleotide polymorph-
ism quality was 525.
Genotyping and linkage analysis
Single nucleotide polymorphism microarray genotyping was performed
using Illumina Human CytoSNP-12v2.1 (Family 3) and Affymetrix 6.0
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single nucleotide polymorphism (Family 2) arrays. Marker saturation
was carried out using existing and newly generated microsatellite
markers (primer sequences available on request). Alleles were size-
fractionated using 8% polyacrylamide gels and DNA was visualized
by silver staining.
Mutation analysis
Unique sequence intronic primers were designed to amplify all poten-
tially pathogenic variants identified within the critical region. Purified
PCR amplification products were sequenced using dye-terminator
chemistry and electrophoresed on an ABI 3130XLA capillary sequencer
(Applied Biosystems). Mutation analysis was carried out using
Mutation Surveyor software v3.20 (SoftGenetics). Both strands of
each product were sequenced.
Fibroblast culture
Human forearm fibroblasts were cultured in Dulbecco’s modified Eagle
medium with 10% foetal bovine serum and antibiotics, after standard
protocols in 75 cm flasks. Cells were dissociated from flasks for analysis
by means of 5 min incubation with 0.05% trypsin with 0.02% EDTA at
37C. Fibroblast pellets were taken up in 0.5 ml Milli-Q water and
freeze-thawed three times. GSL extraction, isolation, 2AA-labelling
and HPLC were performed as previously described (Neville et al.,
2004).
Exoglycosidase digests
Labelled glycans released from fibroblast GSLs were digested for 18 h
at 37C in a total volume of 20 ml with sialidase A, -galactosidase,
b-galactosidase and b-hexosaminidase (Prozyme/Glyko) according to
manufacturer’s instructions. Following digestion, labelled glycans were
separated from enzyme protein using Corning Costar Spin-X
centrifuge tube filters before HPLC, as above.
MALDI mass spectrometry
Released glycans were permethylated (Ciucanu and Costello, 2003)
then analysed on a Shimatzu Resonance MALDI instrument using
2,5-dihydroxybenzoic acid (DHB) matrix per-O-methylation of neutral
carbohydrates directly from aqueous samples for gas chromatography
and mass spectrometry analysis (Ciucanu and Caprita, 2007). Samples
were analysed with two different mass range settings: 350–850 and
850–2000 Da.
Results
Genetic studies
We previously detailed the clinical features of a large Kuwaiti
family with a complex neurodegenerative phenotype (Wilkinson
Figure 1 (A) Pedigrees of Families 1 (Kuwaiti), 2 (Italian) and 3 (Old Order Amish). Segregation of c.1458dup (exon 10;
p.Leu487Thrfs*77), c.852G4C (exon 7; p.Lys284Asn) and c.1514G4A (exon 10; p.Arg505His) variants throughout each family with
mutant allele indicated by ‘ + ’ and wild-type allele indicated by ‘ ’, as well as the sequence chromatogram for each variant. (B) The
position of each sequence variant with regard to domain architecture of the protein where ‘A’ refers to ‘glycosyl transferase, Family 2
domain’, and ‘B’ indicates ‘nucleotide-diphospho-sugar transferases superfamily domain’. (C) Species conservation alignments for the
regions affected by each variant.
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et al., 2005) and a clinical description of the additional
Italian-Canadian and Old Order Amish families is supplied in the
Supplementary material. The most prominent clinical phenotype
common to these families is progressive weakness and spasticity,
affecting the lower extremities, plus or minus the upper
extremities. All affected individuals also manifest apparently non-
progressive cognitive impairment. Additional features included
cerebellar signs, sensory polyneuropathy, pes cavus, stereotypies,
emotional lability and psychiatric illness. Seizure activity was
reported in two of four Amish individuals. Where neuroimaging
was undertaken no abnormalities were reported. Therefore, a clin-
ical diagnosis of complicated hereditary spastic paraplegia had
been assigned to these families, although there are additional fea-
tures present in some affected individuals that provide evidence of
a broader phenotype associated with GM2 synthase deficiency.
To robustly position the gene responsible for this condition, we
first refined the extent of the disease locus previously defined in the
Kuwaiti family using microsatellite markers to chr12:52 012 214–
65 342 437, a 13.33 Mb region containing 317 genes (data not
shown). In order to identify the causative mutation we designed a
custom 1 tiling bait array to capture a targeted region encompass-
ing this region. The target size was 6.25 Mb after repeat masking,
generating 6.2 Gb of data with a mean depth of 570. After filtering
and exclusion of novel sequence variants found to be present in
homozygous state in Kuwaiti controls, only a single likely deleterious
variant remained as potentially causative. This was a frameshift in-
sertion in the last exon of the beta-1,4-N-acetyl-galactosaminyl
transferase 1 (B4GALNT1) gene (Fig. 1; chr12:g.58020671dup;
NM_001478.3: c.1458dup, p.Leu487Thrfs*77), which may there-
fore be likely to encode a transcript that escapes nonsense-mediated
messenger RNA decay surveillance mechanisms and produces a
polypeptide with an altered and elongated C-terminus (Fig. 1).
Dideoxy sequence analysis revealed that the variant cosegregated
with the disease phenotype, with affected individuals being homo-
zygous for the variant, and parents and all unaffected offspring being
heterozygous carriers (Fig. 1). In parallel with this targeted regional
sequencing approach, whole exome sequencing was undertaken
using DNA from a single affected individual from two additional
families with a clinically similar presentation to the Kuwaiti family.
The first of these families, who originate from a small village in the
Frosinone region of central Italy, have two affected offspring from a
consanguineous union (Family 2, Fig. 1). After filtering of variants
only two novel likely deleterious sequence variants were found to be
present in genes located in shared homozygous regions between the
two affected cases detected by a complementary Affymetrix 6.0
single nucleotide polymorphism microarray scan (data not shown),
both of which cosegregated with the disease phenotype as deter-
mined by dideoxy sequence analysis. One was located in OR51S1
(NM_001004758.1: c.821C4T; p.Pro274Leu), an olfactory recep-
tor gene considered an unlikely candidate to cause this condition.
The second variant affects a stringently conserved residue
in B4GALNT1 (Fig. 1; chr12:g.58022646G4C; NM_001478.3:c.
852G4C; p.Lys284Asn) and is predicted to be damaging by
PolyPhen-2, SIFT and PROVEAN. The second DNA sample subject
to exome sequencing was from a single affected individual from an
extended Amish pedigree (Family 3, Fig. 1). This identified another
homozygous likely deleterious sequence alteration in B4GALNT1
(Fig. 1; chr12:g.58020615C4T; NM_001478.3: c.1514G4A;
p.Arg505His), located in 15 Mb region of homozygosity delimited
by markers rs7139287 and rs2717445 (data not shown) shared by
four affected individuals in three Amish nuclear families. This variant
cosegregates with the disease phenotype as determined by dideoxy
sequence analysis and is predicted deleterious by PolyPhen-2, SIFT
and PROVEAN. It was found to be present in a heterozygous state in
two out of 300 Amish control subjects, which is not unexpected of a
founder mutation present in the community. The Amish variant is not
listed in the 1000 Genomes genomic database (comprising 2184
chromosomes) and only a single heterozygous carrier of European
origin was identified out of 13 006 chromosomes analysed in the
National Heart, Lung and Blood Institute Exome Sequencing
Project database (ESP6500SI release). Neither the B4GALNT1
c.1458dup frameshift nor c.852G4C variants are present in publicly
accessible genomic databases, or in 100 ethnically matched control
chromosomes.
Biochemical studies
As the B4GALNT1 variants identified were predicted to abolish
GM2 synthase activity of the encoded polypeptide, we investi-
gated the biochemical effect of the mutation in cultured skin fibro-
blasts from an affected brother and sister from the Italian family,
as these were available for investigation. GM2 ganglioside is a
sialylated GSL that is synthesized in the Golgi apparatus as part
of a complex biosynthetic pathway (Supplementary Fig. 1). GM2
synthase is a GalNAc transferase responsible for synthesizing GM2,
GA2 and GD2 (Pohlentz et al., 1988). If GM2 synthase were
deficient in the affected individuals, no GM2, GA2, GD2 or down-
stream derivatives would be synthesized (blue box, Supplementary
Fig. 1). To test this hypothesis, fibroblasts from both affected in-
dividuals were analysed by generating fluorescently-labelled GSL-
derived oligosaccharides and performing HPLC (Fig. 2) (Neville
et al., 2004). We confirmed the glycan structures of the GSL-
derived oligosaccharides in healthy individuals by comparing
them with commercially available authentic standards, by perform-
ing exoglycosidase digestion and by confirming structures by mass
spectrometry (Supplementary Figs 2 and 3 and Supplementary
Table 1). A representative profile of fibroblast GSLs from an un-
affected individual (Fig. 2A) showed that the major GSL species
detectable were LacCer, Gb3, GM3, GM2 and Gb4. HPLC profiles
from the two affected patients’ fibroblasts (Family 2 Individuals
IV:3 and IV:4) were identical to each other, but differed in several
ways from unaffected fibroblasts. Firstly, there was an increase in
the level of GM3 relative to Gb3 (Fig. 2C). Secondly, there was a
large reduction in the GM2 peak (authenticated by mass spec-
trometry, Supplementary Fig. 2, in the unaffected patient fibro-
blasts), leaving only a minor peak ‘X’, in affected patient cells. To
determine the structure of peak ‘X’, we performed sialidase-A di-
gests on both affected and unaffected fibroblast samples. As ex-
pected, the GM3 glycan was digested to Lac, confirming this
structure in both samples. In the unaffected fibroblasts the GM2
peak was converted to asialo GM2 (GA2) confirming it as GM2
(Fig. 2B). Peak ‘X’ in the affected patients (Fig. 2C) was also
sensitive to sialidase digestion (Fig. 2D). However, in contrast
with the unaffected sample (Fig. 2B), it did not lead to the
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production of GA2 and instead, was converted into either Gb3 or
LacCer, ruling out the presence of GM2 in the affected patient
fibroblasts (Fig. 2D). To establish more specific structural informa-
tion, preparative HPLC was performed collecting individual peaks
(Fig. 2C). When peak ‘X’ was digested with sialidase-A, the peak
shifted to a retention time consistent with Gb3, revealing the
structure to be a previously unreported novel GSL namely sialy-
lated Gb3. To explain this, we hypothesize that in the absence of
functional GM2 synthase in the patient cells there will be a lack of
downstream GSLs as substrates for sialyltransferase, ST3GALII,
and this may be the cause of the ectopic sialylation of Gb3.
Absolute quantities of each individual GSL peak were determined
and are summarized (Supplementary Table 2). The two affected
siblings showed remarkably similar absolute amounts of GSLs
whereas the control sample had 25% less, in total, suggesting
that the patients may have not only altered composition but also
increased GSL levels. Analysis of more samples will be required to
verify this observation. In addition to the sialidase digests, further
digests with -galactosidase, b-galactosidase and b-hexosamini-
dase confirmed the presence of Gb3, LacCer and Gb4 glycan
structures in both samples (data not shown). Similar biochemical
findings were seen when analysing fibroblasts from the Amish
pedigree (Individual IX:1; Supplementary Fig. 2).
Discussion
In the CNS of mammals, ganglioside structures and their expres-
sion levels are highly conserved. Four gangliosides predominate,
namely GM1, GD1a, GD1b and GT1b (Schnaar, 2010). Insights
into the functions of gangliosides have come in part from studying
engineered mice deficient in key glycosyltransferases required for
ganglioside biosynthesis (Schnaar, 2010). For example, when
B4GALNT (GM2 synthase, the enzyme deficient in the patients
in the current study) is deficient in the mouse, none of the
major brain gangliosides are synthesized. Instead, the simple gan-
gliosides GM3 and GD3 are present at higher than normal levels,
as they are synthesized before the biosynthetic block (Takamiya
et al., 1996; Kawai et al., 2000). Indeed, total GSL levels are
comparable in both wild-type and engineered mice, with increased
levels of ‘pre-block’ simple GSLs compensating for the lack of
complex ganglioside biosynthesis (Sun et al., 2004) illustrating
tight control of total GSL levels. As GD3 does not bind to
myelin-associated glycoprotein (MAG), a key mediator of myelin
stability, and GM3 binds poorly to myelin-associated glycoprotein
(Collins et al., 1997), these mice have defective axon:myelin sta-
bility leading to progressive neuropathy, similar to that seen in
MAG-deficient mice (Sun et al., 2004). Wallerian axonal
Figure 2 Representative HPLC profiles for 2-AA labelled glycans released from GSLs isolated from cultured human skin fibroblasts.
Unaffected patient (control; A and B). Affected sister/sibling (C and D) in the Italian family. B and D show the peak shifts,
indicated with dashed arrows, following digestion of the labelled glycans with Sialidase A. Peak ‘X’ (in C) is a previously unreported GSL,
sialylated Gb3.
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degeneration occurs in B4GALNT1 mice leading to impaired motor
coordination and diminished hind-limb reflexes (Sheikh et al.,
1999). In addition, the mice displayed abnormal structures at the
nodes of Ranvier, leading to electrophysiological defects charac-
terized by reduced conduction velocities in motor nerves (Susuki
et al., 2007). It remains to be determined the extent to which the
clinical features of the patients in this study and the engineered
GM2 synthase mouse converge, but loss of complex gangliosides
could potentially disrupt axon:myelin stability in both mouse
and man.
To date, only one other human inherited disease resulting from
a proven ganglioside biosynthetic defect has been described,
namely GM3 synthase deficiency present amongst the Old
Order Amish (Simpson et al., 2004). This presents clinically as a
severe neurological syndrome, which in most patients involves
intractable seizures, but not in the mouse model (Yamashita
et al., 2003), likely because of compensation through o-series
GSL biosynthesis (Supplementary Fig. 1). Here we describe a
second human neurological disease involving a defect in the adja-
cent enzyme acting in the ganglioside biosynthetic pathway in
families of different ethnic backgrounds, including the Amish in
which both known ganglioside disorders are present. All families
show a phenotype consisting mainly of progressive spastic para-
paresis, together with variable learning difficulties, although this
doesn’t appear to be progressive. Clinical examination and nerve
conduction suggest a mild peripheral neuropathy in some of the
cases. The siblings in Family 2 share several unusual traits in add-
ition to paraplegia and intellectual disability: congenital cervical
spinal narrowing, dysmorphological features (prognathism, wide
mouth, deep-set eyes), and tumours (ovarian teratoma and
colonic adenocarcinoma). These features may be merely coinci-
dental, may relate to another genetic disorder, or more likely be
connected to this disorder of ganglioside biosynthesis. The earlier
report of a patient with the biochemical hallmarks of GM2 syn-
thase deficiency at post-mortem (Fishman et al., 1975) remains
genetically unproven. Whether that report describes a more severe
phenotype arising from GM2 synthase deficiency remains unclear,
although this may be unlikely as the mutations described in the
current study and by Boukhris et al. (2013) are all predicted to
result in complete loss of enzyme activity, which has been con-
firmed biochemically in Families 2 and 3 in the current study.
Consequently it therefore remains impossible to determine the
relationship between the cases of proven GM2 synthase deficiency
in the current study, and the historic case report. However, the
biochemical assay we employed may be of use diagnostically in
the future in individuals with clinical features reminiscent of the
complex form of hereditary spastic paraplegia described here.
With the description now of two neurological human diseases
involving defects in two sequentially acting enzymes involved in
the ganglioside biosynthetic pathway, there is the real possibility
that a previously unidentified family of ganglioside deficiency
diseases exists. The study of patients and animal models of
these disorders will pave the way for greater understanding of
the role gangliosides play in neuronal structure and function and
provide insights into the future development of effective
therapies to treat patients afflicted with these devastating
disorders.
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